Abstract
Alzheimer’s disease is a neurodegenerative disorder, marked by dementia, impaired judgment, and a decline in cognitive abilities, that affects over 50 million people worldwide. The etiology of the disease is influenced by a myriad of genetic and environmental factors including APOE4 allele status and sex and can be characterized by a variety of neuropathological markers, such as amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in specific areas of the brain, as well as the dysregulation of certain genes. However, how APOE4 status and sex affect the expression of these biomarkers and the gene dysregulation patterns specific to each brain region have yet to be determined. In this study, statistical and correlational analyses were performed to identify and quantify the relationship between the expression of proteo-transcriptomic biomarkers associated with neurodegenerative disorders and neuronal development in the frontal white matter, parietal cortex, temporal cortex, and hippocampus with patient demographic and genetic information. Further analysis determined whether the observed correlations were brain-region-specific or sex-specific. There was a statistically significant relationship between APOE4 status and degree of Aβ accumulation (P < 0.001) and neurofibrillary tangle formation (P = 0.04). Aβ plaque deposition was found to be more severe in females (P = 0.001) and the intensity of Aβ and NFT formation differed across brain regions (P < 0.001, P = 0.001 respectively). Furthermore, transcriptomic analysis revealed brain-region-specific gene dysregulation patterns. These patterns can identify therapeutic targets for future targeted gene and protein therapies in specific brain regions to treat Alzheimer’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located at: http://aging.brain-map.org/download/index.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at http://aging.brain-map.org/download/index.
